GTPase activating proteins (GAPs) of the centaurin family regulate the actin cytoskeleton and vesicle trafficking through inactivation of the ADP-ribosylation factor (ARF) family of small GTP-binding proteins. We report the functional characterisation of centaurin-α2, which is structurally related to the centaurin-α1 ARF6 GAP. centaurin-α2 contains an N-terminal GAP domain followed by two pleckstrin homology (PH) domains (N-PH and C-PH). In vitro, GFP-centaurin-α2 specifically binds the phosphatidylinositol (PI) 3-kinase lipid products, PI 3,4-P2 and PI 3,4,5-P3 (PIP3), through its C-terminal PH domain. In agreement with this observation, GFP-centaurin-α2 was recruited to the plasma membrane from the cytosol in EGF-stimulated cells in a PI-3-kinase-dependent manner. Moreover, the C-PH domain is sufficient and necessary for membrane recruitment of centaurin-α2. centaurin-α2 shows sustained kinetics of PI-3-kinase-mediated membrane recruitment in EGF-stimulated cells, owing to its binding to PI 3,4-P2. centaurin-α2 prevents ARF6 translocation to, and cortical actin formation at, the plasma membrane, which are phenotypic indications for ARF6 activation in EGF-stimulated cells. Moreover, the constitutively active mutant of ARF6 reverses the effect of centaurin-α2 on cortical actin formation. The membrane targeted centaurin-α2 is constitutively active. Together, these studies indicate that centaurin-α2 is recruited in a sustained manner to the plasma membrane through binding to PI 3,4-P2 and thereby regulates actin reorganisation via ARF6.

Phosphatidylinositol (PI) 3-kinase phosphorylates the 3′ position of the inositol ring of PI and its derivatives to generate the 3-phosphorylated PI lipids, including PI 3-P, PI 3,4-P2 and PI 3,4,5-P3 (PIP3) (Vanhaesebroeck et al., 2001). PI 3,4-P2 is also produced from dephosphorylation of PIP3 by 5-phosphatases such as the inositol polyphosphate 5-phosphatase (PIPP) (Ooms et al., 2006). For this reason, PIP3 production in stimulated platelets is immediate and transient whereas PI 3,4-P2 accumulation is slightly delayed and significantly more sustained (Franke et al., 1997). Both PIP3 and PI 3,4-P2 play major roles as second messengers in many cellular functions such as cell migration and vesicle budding. These lipid second messengers function mainly by acting as site-specific ligands for the recruitment and/or activation of intracellular proteins required for the formation of signalling complexes at the plasma membrane. A large number of downstream targets, including ARF regulators, such as cytohesins and centaurins, have been identified for these lipids (Rameh and Cantley, 1999). Most of these proteins contain modules, typically pleckstrin homology (PH) domains, that are capable of binding to the inositol head group of PIP3 and/or PI 3,4-P2.

ADP-ribosylation factors (ARFs) are a family of monomeric small GTPases that are ubiquitously expressed and play important roles in the regulation of cellular processes such as membrane trafficking and cytoskeletal actin reorganisation, which are vital for cell adhesion, cell migration and cell polarity (D'Souza-Schorey and Chavrier, 2006). They do so by shuttling between an inactive GDP-bound and an active GTP-bound form. To date, six members of this family (ARFs1-6) have been identified in mammalian cells (Kahn et al., 2006; Moss and Vaughan, 1998). ARF1 and ARF6 are the least related and also the best studied of the ARF family. ARF1 cycles between the cytosol and the Golgi depending on the bound nucleotide status, localising to the cytosol in the GDP-bound form and attaching to the Golgi membrane through the N-terminal myristoylation signal in the GTP-bound form (Donaldson et al., 2005). By contrast, ARF6 localises to endosomes in its GDP-bound form and to the plasma membrane in its GTP-bound form (Donaldson, 2003). ARF1 mainly functions in the perinuclear areas, mediating the recruitment of cytosolic coat proteins such as COPI and AP1 onto the membranes required for vesicle budding at the Golgi (Donaldson et al., 2005). By contrast, ARF6 primarily functions at the cell periphery, mediating membrane and cell surface receptor endocytosis as well as actin cytoskeleton rearrangements beneath the plasma membrane (D'Souza-Schorey and Chavrier, 2006; Donaldson, 2003).

The activation-inactivation cycle of ARFs is regulated by GTP-exchange factors (GEFs) and GTPase activating proteins (GAPs) (Moss and Vaughan, 1998; Randazzo et al., 2000). GEFs activate ARFs by catalysing the exchange of ARF bound GDP for GTP. In the active GTP-bound state, ARFs transmit the signal downstream by interacting with specific effector proteins such as the GGA coat protein family and PIP kinases (D'Souza-Schorey and Chavrier, 2006; Nie et al., 2003). GAPs inactivate ARFs by stimulating hydrolysis of the ARF bound GTP to GDP. Although ARF function requires the regulated shuttling between an active GTP-bound and an inactive GDP-bound form, very little is known about the regulation of ARF GTPases by extracellular stimuli. Recent identification of ARF GEFs, such as cytohesins (cytohesins 1-3), and ARF GAPs, such as centaurin-α1 and ARAP3, as PIP3-binding proteins has highlighted their potential to serve as signal transducers that link upstream PI 3-kinase to the regulation of ARF GTPases (Cullen and Venkateswarlu, 1999; Hawadle et al., 2002; Jackson et al., 2000).

Centaurin proteins are a family of GAPs for the ARF family of small G proteins (Randazzo and Hirsch, 2004). centaurin-α1 (also known as PIP3BP/p42IP4) was originally identified as a PIP3 or its inositol head group, inositol 1,3,4,5-tetrakisphosphate (IP4), binding protein (Hammonds-Odie et al., 1996; Stricker et al., 1997; Tanaka et al., 1999). This protein acts as a PIP3-dependent ARF6 GAP that regulates GPCR internalisation and actin reorganisation (Lawrence et al., 2005; Venkateswarlu et al., 1999a; Venkateswarlu et al., 2004; Venkateswarlu et al., 2005). centaurin-α1 contains an N-terminal ARF GAP domain and two adjacent PH domains [one in the middle (N-PH) and the other at the C terminus (C-PH)] that are required for binding to PIP3 (Venkateswarlu et al., 1999a). centaurin-α1 localises to the cytosol and nucleus, and contains a nuclear localisation signal at the N terminus (Tanaka et al., 1999; Venkateswarlu and Cullen, 1999). It associates with and is phosphorylated by PKC isoforms (Zemlickova et al., 2003). centaurin-α1 has a restricted tissue distribution and is expressed particularly at high levels in rat brain, indicating that it is important for neuronal functions (Aggensteiner and Reiser, 2003; Hammonds-Odie et al., 1996; Venkateswarlu and Cullen, 1999). centaurin-α1 expression is increased in neurons of patients with Alzheimer's disease (AD) (Reiser and Bernstein, 2002). Moreover, it interacts with casein kinase Iα, which hyperphosphorylates the β-amyloid precursor protein in the brains of AD patients (Dubois et al., 2001). To date, the significance of the increase in centaurin-α1 protein expression in terms of AD pathology is unknown.

Whitley et al. (Whitley et al., 2002) identified centaurin-α2 as a novel 43 kDa protein by screening a rat adipocyte cDNA library. Centaurin-α2 shares 58% amino acid identity with centaurin-α1 and contains the same domain structure as centaurin-α1, an N-terminal GAP domain followed by two PH domains (N-PH and C-PH). However, there are marked differences between centaurin-α1 and centaurin-α2 in terms of the chromosomal localisation, tissue distribution and phosphorylation sites. The gene for human centaurin-α2 is located on chromosome 17 near to the neurofibromatosis type 1 (NF1) gene, whereas the centaurin-α1 gene is located on human chromosome 7 (Hanck et al., 2004). In contrast to centaurin-α1, which is expressed mainly in brain, centaurin-α2 is expressed in many tissues such as liver and heart but not in brain (Hanck et al., 2004; Whitley et al., 2002). centaurin-α1 contains a nuclear localisation signal at its N terminus, which centaurin-α2 lacks. Similarly centaurin-α1 contains two PKC phosphorylation sites (one in the GAP domain, S87, and the other in the C-PH domain, T276), which are absent in centaurin-α2 (Zemlickova et al., 2003). Moreover, the function of centaurin-α2 is not known. Therefore, in this study we sought to determine the PI binding and ARF GAP activity of centaurin-α2 in intact cells in order to understand its cellular functions and regulation. We demonstrate that centaurin-α2 is a target for activated PI 3-kinase that is recruited, in a sustained manner, to the plasma membrane and thereby negatively regulates ARF6-mediated cytoskeleton actin reorganisation.

Centaurin-α2 interacts with PIP3 and PI 3,4-P2 via the C-terminal PH domain in vitro

Since centaurin-α2 is structurally related to PIP3 binding centaurin-α1, we hypothesised that centaurin-α2 may bind to PIP3 or other PI 3-kinase lipid products. To assess whether centaurin-α2 associates directly with PI 3-kinase lipid products, we incubated the lysate of cells expressing either GFP or GFP-centaurin-α2 with avidin beads alone (control beads) or coupled to biotinylated PI 3-kinase lipid products (PIP3, PI 3,4-P2 and PI 3-P) or PI 4,5-P2. The GFP-centaurin-α2 selectively bound to the avidin beads containing either PI 3,4-P2 or PIP3 but not to the control beads or the beads that contained either PI 3-P or PI 4,5-P2 (Fig. 1A). The amount of GFP-centaurin-α2 bound to PI 3,4-P2 beads was relatively higher than that bound to PIP3 beads. By contrast, GFP alone failed to bind any of the PIs tested under these conditions. This data suggests that centaurin-α2 specifically interacts with PIP3 and PI 3,4-P2, albeit with slightly higher affinity to PI 3,4-P2.

We subsequently examined the sensitivity of centaurin-α2 interaction with the PI 3-kinase products by competition binding experiments (Fig. 1B). PI 3-P failed to block centaurin-α2 binding to PI 3,4-P2 beads whereas PI 4,5-P2 partially blocked the binding but only at a very high concentration (10 μM). However, PI 3,4-P2 and PIP3 blocked centaurin-α2 binding to PI 3,4-P2 beads, the former being more effective. The concentration required to block 50% of the binding (EC50) of PI 3,4-P2, PIP3, PI 4,5-P2 and PI 3-P is calculated from the displacement curve (Fig. 1B) as 20 nM, 87.6 nM, >10 μM and >10 μM, respectively. As centaurin-α2 contains two PH domains that are known to bind PIs, we generated GFP-tagged centaurin-α2 PH domain mutants by converting the conserved arginine residue to cysteine in either the N-PH (R152C), or the C-PH (R276C) alone or in both the PH domains [R152C/R276C; double PH mutant (DM)]. We then analysed their ability to bind PIs to determine which PH domain is required for the binding to PI 3,4-P2 and PIP3 (Fig. 1C). Binding of the R152C mutant to PI 3,4-P2 and PIP3 beads was identical to that of the wild-type (WT) protein whereas the R276C and DM mutants of centaurin-α2 failed to bind to PI 3,4-P2 and PIP3 beads under the same conditions. These results indicate that centaurin-α2 interacts with PI 3,4-P2 and/or PIP3 through the C-PH domain.

Centaurin-α2 is recruited to the plasma membrane in EGF-stimulated PC12 cells

Centaurin-α1 is recruited to the plasma membrane from the cytosol in PC12 cells after stimulation with EGF (Venkateswarlu et al., 1999a). Since centaurin-α2 is structurally related to centaurin-α1, we tested whether centaurin-α2 is also recruited to the plasma membrane in EGF-stimulated cells. For this purpose, we expressed GFP-centaurin-α2 in PC12 cells and analysed subcellular localisation before and after stimulation with EGF by live-cell imaging. Before stimulation, this protein showed a diffuse cytoplasmic localisation. After stimulation with EGF-, GFP-centaurin-α2, but not GFP alone, showed a clear relocation to the plasma membrane within 2 minutes (Fig. 2A). Similar results were obtained with FLAG-tagged centaurin-α2 (Fig. 2B), indicating that the large GFP tag had no affect on subcellular localisation of centaurin-α2.

The membrane recruitment of centaurin-α2 is mediated through PI 3-kinase activation

Since EGF activates PI 3-kinase and centaurin-α2 binds PI 3-kinase products in vitro, we tested whether the redistribution of centaurin-α2 is dependent on activation of PI 3-kinase. This was done by using two chemically distinct PI 3-kinase inhibitors, wortmannin and LY294002. We found that both PI 3-kinase inhibitors can completely block the EGF-stimulated redistribution of centaurin-α2 to the plasma membrane (Fig. 3A). Moreover, when centaurin-α2 is co-expressed with Δp85 (a dominant negative mutant of the PI 3-kinase regulatory subunit), the EGF-stimulated membrane recruitment of centaurin-α2 upon was also prevented (Fig. 3A). We then quantified the effect of PI 3-kinase inhibitors on the EGF-induced membrane recruitment of centaurin-α2 (Fig. 3C). 97.5%, 1.3%, 2.5% and 1.5% of transfected cells showed membrane localisation of centaurin-α2 when stimulated with EGF in the presence of DMSO solvent, wortmannin, LY294002 and Δp85, respectively.

To determine whether activation of PI 3-kinase is sufficient for the recruitment of centaurin-α2 to the plasma membrane, PC12 cells were co-transfected with GFP-centaurin-α2, and either a membrane-bound, constitutively active, PI 3-kinase (membPI3K) or a control membrane-bound kinase-dead PI 3-kinase (membPI3K-KD), and the subcellular localisation of GFP-centaurin-α2 was analysed in the absence of EGF. centaurin-α2 was recruited to the membrane in cells co-transfected with membPI3K but not membPI3K-KD (Fig. 3B). We found that 96% cells co-transfected with membPI3K, compared to 6% of cells co-expressing membPI3K-KD, showed GFP-centaurin-α2 localisation at the plasma membrane (Fig. 3C). These results suggest that the activation of PI 3-kinase is responsible for the membrane recruitment of centaurin-α2.

The C-terminal PH domain is sufficient and necessary for membrane recruitment of centaurin-α2

We next determined which PH domain of centaurin-α2 is required for EGF-stimulated membrane recruitment. When the GFP-tagged PH mutants (Fig. 4A) were expressed in PC12 cells, we found that the N-PH mutant (R152C), but not the C-PH mutant (R276C) or the double PH mutant (DM), was recruited to the plasma membrane after stimulation (Fig. 4B). In addition, the mutation of the highly conserved arginine residue (corresponding to the arginine in centaurin-α1 required for the GAP activity) in the GAP domain to cysteine (R53C) had no affect on the EGF-stimulated membrane recruitment of centaurin-α2. Consistent with this, R276C and DM, but not R152C, failed to localise at the plasma membrane when co-expressed with membPI3K (data not shown). 97%, 96%, 92%, 2% and 1% of cells transfected with wild-type (WT) centaurin-α2, R53C, R152C, R276C and DM, respectively, were found to show EGF-induced recruitment to the membrane (Fig. 4C). Consistent with the in vitro PI binding data, this result suggests that the C-PH domain appears to be solely responsible for the PI 3-kinase-dependent membrane recruitment of centaurin-α2.

Centaurin-α2 shows sustained recruitment to the membrane in EGF-stimulated cells

We have also examined the kinetics of membrane recruitment of centaurin-α2 in single cells using the live-cell imaging approach (Fig. 5A). In EGF-stimulated PC12 cells, the membrane recruitment of GFP-centaurin-α2 became visible within 30 seconds after addition of the stimulus, was completed within 90-120 seconds and was sustained (visible up to 60 minutes after stimulation). centaurin-α2 binds to PIP3 and PI 3,4-P2 in vitro with high affinity. Since PIP3 production is transient whereas PI 3,4-P2 accumulation is more sustained in agonist-stimulated cells, we reasoned that centaurin-α2 is retained at the plasma membrane in a sustained fashion through binding to PI 3,4-P2. To investigate this possibility, the kinetics of centaurin-α2 recruitment were compared with the EGF-stimulated redistribution of GFP-tagged cytohesin 3, TAPP1 and PLC δ1-PH, which have been used as biosensors in intact cells to detect PIP3, PI 3,4-P2 and PI 4,5-P2, respectively (Oatey et al., 1999; Ooms et al., 2006). The EGF-stimulated membrane recruitment of cytohesin 3 occurred rapidly (within 30 seconds) and transiently, with visible membrane localisation disappearing by 16 minutes after stimulation. By contrast, the kinetics of EGF-induced plasma membrane redistribution of TAPP1 (sustained) were similar to those of the centaurin-α2. The PLC δ1-PH domain binds to the constitutively present PI 4,5-P2 and therefore, as expected, showed constitutive association with the plasma membrane.

The above results suggest that the sustained recruitment of centaurin-α2 to the membrane in EGF-stimulated cells is likely to be due to its binding to PI 3,4-P2. To investigate this we used two inositol polyphosphate phosphatases, PIPP, which hydrolyses PIP3 to PI 3,4-P2, and type 1α inositol polyphosphate 4-phosphatase (4-phosphatase), which specifically hydrolyses PI 3,4-P2 to PI 3-P (Ivetac et al., 2005; Ooms et al., 2006). We co-expressed either GFP-tagged centaurin-α2, cytohesin 3 or TAPP1 with control empty vector, HA-PIPP or FLAG-4-phosphatase in PC12 cells and assessed the plasma membrane recruitment of GFP-tagged proteins after stimulation with EGF (Fig. 5B). Under basal conditions, none of the proteins associated with the plasma membrane in cells expressing control empty vector, PIPP or 4-phosphatase (data not shown). Upon stimulation with EGF, recruitment of cytohesin 3 to the membrane was observed in control empty vector and 4-phosphatase-expressing cells whereas TAPP1 and centaurin-α2 were seen at the plasma membrane in control empty vector and PIPP-expressing cells. To analyse the data more quantitatively, we determined the percentage of transfected cells in which the GFP-tagged proteins were recruited to the plasma membrane in response to EGF-stimulation (Fig. 5C). Plasma membrane localisation of GFP-cytohesin 3 was seen in 88% of cells expressing control empty vector compared to 21% and 91% of cells exogenously expressing PIPP and 4-phosphatase, respectively. This suggests that the decrease in PIP3 accumulation at the plasma membrane was due to overexpression of PIPP. By contrast, TAPP1 associated with the membrane in 83%, 79% and 19% of cells expressing control empty vector, PIPP or 4-phosphatase, respectively, indicating a reduction in the plasma membrane PI 3,4-P2 levels after ectopic expression of 4-phosphatase. Similar to TAPP1, centaurin-α2 was detected at the plasma membrane in 86%, 88% and 17% of cells expressing control empty vector, PIPP or 4-phosphatase, respectively. The inhibition of recruitment of centaurin-α2 to the membrane with 4-phosphatase overexpression indicates that sustained recruitment of centaurin-α2 to the membrane is indeed a result of its binding to plasma membrane PI 3,4-P2.

Centaurin-α2 prevents ARF6 translocation to and cortical actin formation at the plasma membrane

Centaurin-α1 inhibits the redistribution of ARF6 to the plasma membrane and cortical actin formation in the EGF-stimulated cells by acting as a PIP3-dependent GAP for ARF6 in vivo (Venkateswarlu et al., 2004). Since centaurin-α2 contains a GAP domain similar to that of centaurin-α1 and is recruited to the plasma membrane, we examined whether centaurin-α2 would also inhibit the recruitment of ARF6 to the plasma membrane and cortical actin formation by acting as an in vivo ARF6 GAP. In unstimulated cells, ARF6 showed a punctate distribution, indicative of endosomal localisation, when co-expressed with either control GFP or GFP-centaurin-α2, suggesting that centaurin-α2 does not affect ARF6 localisation under basal conditions (Fig. 6). In EGF-stimulated cells co-expressing ARF6-HA and GFP, ARF6 localised to the plasma membrane. However, EGF-stimulated cells co-transfected with GFP-centaurin-α2 (WT) and ARF6-HA showed the recruitment of centaurin-α2 to the plasma membrane whereas ARF6 was not. Neither the GAP inactive mutant (R53C), which is able to bind PIP3 and/or PI 3,4-P2, or the GAP active DM, which is unable to bind PIP3 and/or PI 3,4-P2, of centaurin-α2 were able to inhibit ARF6 redistribution in EGF-stimulated cells. This suggests that centaurin-α2 requires both its ARF GAP activity and association with the plasma membrane to inhibit the ARF6 activation.

We then examined cortical actin formation in EGF-stimulated cells expressing GFP-centaurin-α2 as a means of studying the effect of centaurin-α2 on the endogenous ARF6 activation (Fig. 6). In the unstimulated condition, the actin network in the control GFP-transfected cells was similar to that in cells transfected with GFP-centaurin-α2, indicating that centaurin-α2 had no effect on the actin network. EGF-induced cortical actin formation was observed in control GFP-expressing cells, but not in the GFP-centaurin-α2-expressing cells, suggesting that centaurin-α2 prevented cortical actin formation in EGF-stimulated cells. However, the GAP (R53C) and DM mutants of centaurin-α2 were unable to prevent cortical actin formation in EGF-stimulated cells. This analysis also suggests that the inhibition of EGF-induced cortical actin formation was dependent on both the plasma membrane recruitment and the GAP activity of centaurin-α2.

The constitutively active mutant of ARF6 (ARF6Q67L) reverses the inhibitory effect of centaurin-α2 on cortical actin formation

We next analysed whether centaurin-α2 could affect EGF-stimulated cortical actin formation by inhibiting ARF6 activation using ARF6Q67, which acts as a dominant negative mutant for centaurin-α2. ARF6Q67L, but not the constitutively active mutant of ARF1 (ARF1Q71L), reversed the inhibition of cortical actin formation by centaurin-α2 in EGF-stimulated cells (Fig. 7). This indicates that centaurin-α2 prevents EGF-stimulated cortical actin formation by inhibiting ARF6 activation.

The membrane targeted centaurin-α2 is constitutively active

To study whether PIP3 and/or PI 3,4-P2 are required just for the membrane recruitment of centaurin-α2 or for both the membrane recruitment and activation of centaurin-α2, we artificially targeted centaurin-α2 (WT) and its GAP (R53C) and DM mutants to the plasma membrane by attaching the CAAX motif of K-Ras to the C terminus and analysed their effect on the redistribution of ARF6 to the plasma membrane by cytohesin 2CAAX, the plasma membrane-targeted ARF6 GEF that activates ARF6 constitutively (Venkateswarlu et al., 2004). GFP-centaurin-α2CAAX WT and DM, but not R53C, inhibited the constitutive re-distribution of ARF6 to the plasma membrane (Fig. 8). This result suggests that centaurin-α2 requires PIP3 and/or PI 3,4-P2 for recruitment to the plasma membrane but not for its activity.

Many cytosolic proteins are reversibly recruited to the plasma membrane to reach their substrate and/or to become activated. The membrane recruitment is often accomplished by protein-lipid or protein-protein interactions, which can be mediated by PH and phosphotyrosine binding (PTB) domains. PH domains generally bind PIs, as in the case of centaurin-α1 (Venkateswarlu et al., 1999a), whereas PTB domains interact with phosphotyrosine residues of plasma membrane-localised receptors, as in the case of Shc (Ferguson et al., 2000). centaurin-α2 contains two PH domains, suggesting that this protein may be recruited to the membranes by binding to PI via the PH domains. We therefore first analysed its in vitro PI binding specificity. This analysis indicates that centaurin-α2 binds preferentially to PI 3,4-P2 and PIP3, which are produced by PI 3-kinase, by its C-PH domain. Consistent with the in vitro PI binding data, we found that centaurin-α2 shows growth factor-stimulated and wortmannin (a PI 3-kinase inhibitor)-sensitive translocation from the cytosol to the plasma membrane. Furthermore, we have shown that active PI 3-kinase is sufficient for the recruitment of centaurin-α2 to plasma membrane through the C-PH domain. A recent study, however, has shown that centaurin-α2 binds to PIP3 in vitro and it localises constitutively to the plasma membrane in a wortmannin-sensitive manner (Hanck et al., 2004). In this study, the transfected cells were not serum starved before analysing centaurin-α2 subcellular location. We also found that centaurin-α2 shows membrane localisation in various cell lines (PC12, COS7, HeLa and HEK293) when the transfected cells were not serum starved, indicating that centaurin-α2 retains at the membrane probably by binding to the serum-activated PI 3-kinase products (data not shown).

TAPP 1 and 2 specifically bind PI 3,4-P2 and therefore have recently been used as biosensors to detect this phospholipid (Ooms et al., 2006). TAPP 1 and 2 show sustained kinetics of PI 3-kinase-mediated membrane recruitment in activated B lymphocytes (Marshall et al., 2002). Like TAPP 1 and 2, centaurin-α2 shows sustained PI 3-kinase-mediated recruitment to the plasma membrane in growth factor-stimulated cells. Moreover, overexpression of 4-phosphatase inhibits the membrane retention of centaurin-α2 in growth factor-stimulated cells. Together, these studies indicate that centaurin-α2 is also retained at the membrane by binding to PI 3,4-P2. Consistent with this, Franke et al. (Franke et al., 1997) found in platelets that the time course of the activation of PKB, which binds both PIP3 and PI 3,4-P2, reflects the more sustained accumulation of PI 3,4-P2 than the transient appearance of PIP3. We have shown that centaurin-α1 binds PIP3 and is recruited to the plasma membrane, where it functions as an in vivo GAP for ARF6 (Venkateswarlu et al., 2004). Similar to centaurin-α1, centaurin-α2 is localised to the plasma membrane in a PI 3-kinase-dependent manner. However, there is a difference in how these two proteins are recruited to the plasma membrane. Recruitment of centaurin-α1 to the membrane is transient whereas centaurin-α2 shows sustained membrane localisation in growth factor-stimulated cells, indicating that they are regulated differently.

Centaurin-α2 shows high amino acid sequence similarity to centaurin-α1, particularly in the GAP domain (81% similarity), suggesting that it may also act as an ARF6 GAP. In order to address this, we looked at the effect of centaurin-α2 on ARF6 localisation and cortical actin formation as a read-out for cytoskeletal actin rearrangements, one of the well established ARF6 cellular functions, in EGF-stimulated cells. Our studies demonstrate that centaurin-α2 also displays GAP activity towards ARF6. Moreover, like centaurin-α1, the GAP activity is mediated via the GAP domain and is specific for ARF6 with the constitutively active mutant of ARF6, ARF6Q67L, but not that of ARF1, preventing inhibition of cortical actin formation in agonist-stimulated cells. In addition, we have shown that the distribution of centaurin-α2 in intact cells is predominantly cytosolic. However, unlike centaurin-α1, centaurin-α2 has no association with the nucleus. Since centaurin-α1 has a very narrow tissue distribution and centaurin-α2 shows a much broader tissue distribution, it is likely that centaurin-α2 acts as an ARF6 GAP in non neuronal cells whereas centaurin-α1 may well be important in neurological signalling. There is already evidence to suggest that centaurin-α1 may be involved in Alzheimer's disease (Reiser and Bernstein, 2002; Reiser and Bernstein, 2004). Interestingly, there have been reports of centaurin-α1 interacting with the nuclear protein nucleolin (Dubois et al., 2003; Reiser and Bernstein, 2004) suggesting that centaurin-α1 may well also play a role in nuclear signalling. Centaurin-α2 gene deletion has been found in a majority of neurofibromatosis type I patients who show an earlier onset of cutaneous neurofibromas dysmorphic facial features, and lower IQ values, indicating that this protein may contribute to the severe phenotype of these patients (Jenne et al., 2000).

In conclusion, we have shown that, like centaurin-α1, the PI 3-kinase-dependent plasma membrane association of centaurin-α2 is required for its involvement in ARF6-mediated actin cytoskeleton remodelling. However, the recruitment of centaurin-α1 to the membrane is transient whereas that of centaurin-α2 is sustained. This study should help us in understanding the function of the centaurin-α subfamily GAPs in cellular events requiring actin rearrangements, such as regulated exocytosis and cell motility, which are all known to be regulated by ARF6.

Plasmid constructs

The full-length human centaurin-α2 cDNA was amplified from mammalian gene collection clone 45054 (MRC-UK gene service) by PCR, using High Fidelity Taq DNA polymerase (Roche Applied Science) and sequence-specific primers containing EcoRI (sense) and SalI (antisense) restriction sites. The cDNA was digested with EcoRI and SalI, and cloned into the same sites of pCMV-Tag2b (Stratagene) for expression as a FLAG-tagged fusion protein and pEGFPC2 vector (Clontech) for expression as a green fluorescent protein (GFP)-tagged fusion protein in mammalian cells. The centaurin-α2 R53C, R152C and R276C mutants were generated using the Quickchange II Site-Directed Mutagenesis kit (Stratagene). The double mutant (DM; R152C/R276C) of centaurin-α2 in pEGFPC2 was generated by replacing the 0.4 kb SacI-SalI fragment of the R152C mutant with the corresponding fragment from the R276C mutant. pEGFP-centaurin-α2 and its mutants were membrane targeted by attaching a C-terminal CAAX motif using PCR and 3′-primer containing the coding sequence for the CAAX motif from K-Ras (KDGKKKKKKSKTKCVIM) as described previously (Venkateswarlu and Cullen, 2000; Venkateswarlu et al., 2004). The ARF6-HA/pXS, ARF6Q67L-HA/pXS and ARF1Q71L-HA/pXS constructs, kindly provided by Julie Donaldson (National Institute of Health), were used to express ARF proteins with a C-terminal hemagglutinin (HA) epitope tag in mammalian cells. Cytohesin 3-pEGFPC1 and Δp85 constructs were described previously (Venkateswarlu et al., 1998b; Venkateswarlu et al., 1999b). TAPP1-pEGFPC1 was kindly provided by Dario Alessi (Dundee University, UK), PLCδ1-PH/pEGFPC1 was a gift from Tamas Balla (NIH), HA-PIPP and FLAG-4-phosphatase vectors were kindly provided by Christina Mitchell (Monash University, Australia), membPI3K and membPI3K-KD were from Doreen Cantrell (Dundee University, UK).

Cell culture and transient transfection

HeLa and COS7 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 2 mM glutamine, 100 IU/ml of penicillin, 0.1 mg/ml of streptomycin sulphate and 10% foetal calf serum (full-serum medium) under 5% CO2 at 37°C. PC12 cells were maintained in the full-serum medium containing 5% horse serum. For transient transfections, the cells were transfected at approximately 70% confluency, with plasmid DNA using Genejuice (Novagen) according to the manufacturer's instructions.

In vitro PI binding assay

This assay was performed as described previously (Rao et al., 1999). Briefly, COS7 cells transfected with GFP or GFP-tagged centaurin-α2 or its mutants for 2 days were lysed in lysis buffer (10 mM Hepes, pH 7.4, 150 mM NaCl, 0.5% Nonidet P-40, 5 mM dithiothreitol) containing 1% protease inhibitors mix (Sigma). The cell lysates were incubated with avidin beads (Pierce) or avidin beads coupled to biotinylated PI (Cell Signals, USA) for 2 hours at 4°C. For competition binding experiments, biotinylated PI 3,4-P2 beads were incubated with the cell lysate in the presence of 1 nM to 10 μM nonbiotinylated water soluble (diC8) PIs (Cell Signals). The beads were washed twice with lysis buffer and the bound proteins were eluted by boiling the beads in sodium dodecyl sulphate (SDS) sample buffer. The proteins were then separated by SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to a polyvinylidene difluoride (PVDF) membrane (Whatman). The blots were analysed by immunoblotting using an anti-GFP polyclonal antibody (Santa Cruz Biotechnology) and scanned using Scion Image™ (Scion Corporation) to ascertain relative intensities of the bands (Venkateswarlu, 2003).

Live cell imaging of PC12 cells

This was carried out as described previously with a few modifications (Venkateswarlu et al., 1998a; Venkateswarlu et al., 1998b). Briefly, PC12 cells plated onto polylysine (0.1 mg/ml; Sigma)-coated 22 mm coverslips were transfected with 2 μg of GFP-tagged protein expression plasmid. After 2 days transfection, cells were serum starved overnight and washed three times with Krebs-Ringer phosphate buffer (K-R buffer; 136 mM NaCl, 4.7 mM KCl, 1.25 mM MgSO4 1.25 mM CaCl2, 5 mM NaPO4, 2 mM NaHCO3 and 25 mM Hepes, pH 7.4), and then imaged using a Leica confocal microscope. Basal images were taken before adding 0.1 μg/ml of epidermal growth factor (EGF; Sigma). Images were then taken every 10 seconds for 2 minutes, then every 2 minutes for 18 minutes and finally for every 10 minutes for 40 minutes to follow any movement of the GFP-tagged protein with a 100× oil immersion lens. All images presented are single sections in the z plane.

Fluorescence imaging of fixed cells

PC12 cells were transfected with expression plasmids encoding GFP-tagged protein or GFP-tagged protein and Δp85. After 2 days, cells were serum starved overnight, and stimulated for 5 minutes at 37°C in K-R buffer alone or K-R buffer containing 0.1 μg/ml EGF. The transfected cells were incubated with 0.1 μM wortmannin (Tocris, Bristol, UK) or 50 μM LY294002 (Tocris) for 15 minutes at 37°C prior to stimulation with EGF, where indicated. Cells were then fixed with 4% paraformaldehyde, washed three times with phosphate-buffered saline (PBS) and mounted on glass slides using mounting solution [0.1 M Tris-HCl, pH 8.5, 10% Mowiol (Calbiochem) and 50% glycerol, containing 2.5% DABCO (Sigma)]. Confocal images were obtained using a Leica confocal microscope with a 100× oil immersion lens.

Immunofluorescent staining

HeLa or PC12 cells, plated onto 13 mm coverslips, were transiently transfected with the indicated expression plasmids. After 2 days, cells were serum starved overnight and stimulated with or without 0.1 μg/ml EGF for 5 minutes. After the stimulation, cells were fixed with 4% paraformaldehyde, permeabilised with 0.2% Triton X-100 in PBS, and then blocked with blocking buffer, 1% BSA in wash buffer (PBS+0.1% Triton X-100). The cells were incubated with anti-FLAG monoclonal M2 (Sigma), anti-HA monoclonal HA11 (Covance) or anti-Myc monoclonal 9E10 (Santa Cruz) primary antibody for 1 hour, and washed three times with wash buffer. Cells were then incubated with either a Rhodamine-conjugated anti-mouse secondary antibody (Jackson Laboratories), or a Rhodamine-conjugated phalloidin (Sigma) when staining actin, in blocking buffer for 1 hour, and washed three times with wash buffer. The cells were mounted on slides with mounting solution. Immunofluorescent staining was visualised using a Leica confocal microscope with a 100× oil immersion lens.

V.K. was a recipient of Biotechnology and Biological Sciences Research Council (BBSRC) UK David Phillips Research Fellowship and H.Y. holds an Overseas Research Scholarship and Bristol University Studentship. K.G.B. received an Medical Research Council (MRC) UK PhD studentship. We thank the MRC UK for providing an Infrastructure Award to establish the School of Medical Sciences Cell Imaging Facility in Bristol University and Mark Jepson and Alan Leard for their assistance. We would also like to thank Dario Alessi, Doreen Cantrell, Christina Mitchell, and Julie Donaldson and Tamas Balla for providing various plasmid constructs described in this manuscript. This work was supported by the grants from BBSRC UK and MRC UK. We also thank Elaine Mo and Hilary Roberts for careful review of the manuscript.

Aggensteiner, M. and Reiser, G. (
). Expression of the brain-specific membrane adapter protein p42IP4/centaurin alpha, a Ins(1,3,4,5)P4/PtdIns(3,4,5)P3 binding protein, in developing rat brain.
Brain Res. Dev. Brain Res.
Cullen, P. J. and Venkateswarlu, K. (
). Potential regulation of ADP-ribosylation factor 6 signalling by phosphatidylinositol 3,4,5-trisphosphate.
Biochem. Soc. Trans.
D'Souza-Schorey, C. and Chavrier, P. (
). ARF proteins: roles in membrane traffic and beyond.
Nat. Rev. Mol. Cell Biol.
Donaldson, J. G. (
). Multiple roles for Arf6: sorting, structuring, and signaling at the plasma membrane.
J. Biol. Chem.
Donaldson, J. G., Honda, A. and Weigert, R. (
). Multiple activities for Arf1 at the Golgi complex.
Biochim. Biophys. Acta
Dubois, T., Kerai, P., Zemlickova, E., Howell, S., Jackson, T. R., Venkateswarlu, K., Cullen, P. J., Theibert, A. B., Larose, L., Roach, P. J. et al. (
). Casein kinase I associates with members of the centaurin-alpha family of phosphatidylinositol 3,4,5-trisphosphate-binding proteins.
J. Biol. Chem.
Dubois, T., Zemlickova, E., Howell, S. and Aitken, A. (
). Centaurin-alpha 1 associates in vitro and in vivo with nucleolin.
Biochem. Biophys. Res. Commun.
Ferguson, K. M., Kavran, J. M., Sankaran, V. G., Fournier, E., Isakoff, S. J., Skolnik, E. Y. and Lemmon, M. A. (
). Structural basis for discrimination of 3-phosphoinositides by pleckstrin homology domains.
Mol. Cell
Franke, T. F., Kaplan, D. R., Cantley, L. C. and Toker, A. (
). Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate.
Hammonds-Odie, L. P., Jackson, T. R., Profit, A. A., Blader, I. J., Turck, C. W., Prestwich, G. D. and Theibert, A. B. (
). Identification and cloning of centaurin-alpha. A novel phosphatidylinositol 3,4,5-trisphosphate-binding protein from rat brain.
J. Biol. Chem.
Hanck, T., Stricker, R., Sedehizade, F. and Reiser, G. (
). Identification of gene structure and subcellular localization of human centaurin alpha 2, and p42IP4, a family of two highly homologous, Ins 1,3,4,5-P4-/PtdIns 3,4,5-P3-binding, adapter proteins.
J. Neurochem.
Hawadle, M. A., Folarin, N., Martin, R. and Jackson, T. R. (
). Cytohesins and centaurins control subcellular trafficking of macromolecular signaling complexes: regulation by phosphoinositides and ADP-ribosylation factors.
Biol. Res.
Ivetac, I., Munday, A. D., Kisseleva, M. V., Zhang, X. M., Luff, S., Tiganis, T., Whisstock, J. C., Rowe, T., Majerus, P. W. and Mitchell, C. A. (
). The type Ialpha inositol polyphosphate 4-phosphatase generates and terminates phosphoinositide 3-kinase signals on endosomes and the plasma membrane.
Mol. Biol. Cell
Jackson, T. R., Kearns, B. G. and Theibert, A. B. (
). Cytohesins and centaurins: mediators of PI 3-kinase-regulated Arf signaling.
Trends Biochem. Sci.
Jenne, D. E., Tinschert, S., Stegmann, E., Reimann, H., Nuernberg, P., Horn, D., Naumann, I., Buske, A. and Thiel, G. (
). A common set of at least 11 functional genes is lost in the majority of NF1 patients with gross deletions.
Kahn, R. A., Cherfils, J., Elias, M., Lovering, R. C., Munro, S. and Schurmann, A. (
). Nomenclature for the human Arf family of GTP-binding proteins: ARF, ARL, and SAR proteins.
J. Cell Biol.
Lawrence, J., Mundell, S. J., Yun, H., Kelly, E. and Venkateswarlu, K. (
). Centaurin-{alpha}1, an ADP-ribosylation factor 6 GTPase activating protein, inhibits {beta}2-adrenoceptor internalization.
Mol. Pharmacol.
Marshall, A. J., Krahn, A. K., Ma, K., Duronio, V. and Hou, S. (
). TAPP1 and TAPP2 are targets of phosphatidylinositol 3-kinase signaling in B cells: sustained plasma membrane recruitment triggered by the B-cell antigen receptor.
Mol. Cell Biol.
Moss, J. and Vaughan, M. (
). Molecules in the ARF orbit.
J. Biol. Chem.
Nie, Z., Hirsch, D. S. and Randazzo, P. A. (
). Arf and its many interactors.
Curr. Opin. Cell Biol.
Oatey, P. B., Venkateswarlu, K., Williams, A. G., Fletcher, L. M., Foulstone, E. J., Cullen, P. J. and Tavare, J. M. (
). Confocal imaging of the subcellular distribution of phosphatidylinositol 3,4,5-trisphosphate in insulin- and PDGF-stimulated 3T3-L1 adipocytes.
Biochem. J.
Ooms, L. M., Fedele, C. G., Astle, M. V., Ivetac, I., Cheung, V., Pearson, R. B., Layton, M. J., Forrai, A., Nandurkar, H. H. and Mitchell, C. A. (
). The inositol polyphosphate 5-phosphatase, PIPP, Is a novel regulator of phosphoinositide 3-kinase-dependent neurite elongation.
Mol. Biol. Cell
Rameh, L. E. and Cantley, L. C. (
). The role of phosphoinositide 3-kinase lipid products in cell function.
J. Biol. Chem.
Randazzo, P. A. and Hirsch, D. S. (
). Arf GAPs: multifunctional proteins that regulate membrane traffic and actin remodelling.
Cell. Signal.
Randazzo, P. A., Andrade, J., Miura, K., Brown, M. T., Long, Y. Q., Stauffer, S., Roller, P. and Cooper, J. A. (
). The Arf GTPase-activating protein ASAP1 regulates the actin cytoskeleton.
Proc. Natl. Acad. Sci. USA
Rao, V. R., Corradetti, M. N., Chen, J., Peng, J., Yuan, J., Prestwich, G. D. and Brugge, J. S. (
). Expression cloning of protein targets for 3-phosphorylated phosphoinositides.
J. Biol. Chem.
Reiser, G. and Bernstein, H. G. (
). Neurons and plaques of Alzheimer's disease patients highly express the neuronal membrane docking protein p42IP4/centaurin alpha.
Reiser, G. and Bernstein, H. G. (
). Altered expression of protein p42IP4/centaurin-α1 in Alzheimer's disease brains and possible interaction of p42IP4 with nucleolin.
Stricker, R., Hulser, E., Fischer, J., Jarchau, T., Walter, U., Lottspeich, F. and Reiser, G. (
). cDNA cloning of porcine p42IP4, a membrane-associated and cytosolic 42 kDa inositol(1,3,4,5)tetrakisphosphate receptor from pig brain with similarly high affinity for phosphatidylinositol (3,4,5)P3.
FEBS Lett.
Tanaka, K., Horiguchi, K., Yoshida, T., Takeda, M., Fujisawa, H., Takeuchi, K., Umeda, M., Kato, S., Ihara, S., Nagata, S. et al. (
). Evidence that a phosphatidylinositol 3,4,5-trisphosphate-binding protein can function in the nucleus.
J. Biol. Chem.
Vanhaesebroeck, B., Leevers, S. J., Ahmadi, K., Timms, J., Katso, R., Driscoll, P. C., Woscholski, R., Parker, P. J. and Waterfield, M. D. (
). Synthesis and function of 3-phosphorylated inositol lipids.
Annu. Rev. Biochem.
Venkateswarlu, K. (
). Interaction protein for cytohesin exchange factors 1 (IPCEF1) binds cytohesin 2 and modifies its activity.
J. Biol. Chem.
Venkateswarlu, K. and Cullen, P. J. (
). Molecular cloning and functional characterization of a human homologue of centaurin-alpha.
Biochem. Biophys. Res. Commun.
Venkateswarlu, K. and Cullen, P. J. (
). Signalling via ADP-ribosylation factor 6 lies downstream of phosphatidylinositide 3-kinase.
Biochem. J.
Venkateswarlu, K., Oatey, P. B., Tavare, J. M. and Cullen, P. J. (
). Insulin-dependent translocation of ARNO to the plasma membrane of adipocytes requires phosphatidylinositol 3-kinase.
Curr. Biol.
Venkateswarlu, K., Gunn-Moore, F., Oatey, P. B., Tavare, J. M. and Cullen, P. J. (
). Nerve growth factor- and epidermal growth factor-stimulated translocation of the ADP-ribosylation factor-exchange factor GRP1 to the plasma membrane of PC12 cells requires activation of phosphatidylinositol 3-kinase and the GRP1 pleckstrin homology domain.
Biochem. J.
Venkateswarlu, K., Oatey, P. B., Tavare, J. M., Jackson, T. R. and Cullen, P. J. (
). Identification of centaurin-alpha1 as a potential in vivo phosphatidylinositol 3,4,5-trisphosphate-binding protein that is functionally homologous to the yeast ADP-ribosylation factor (ARF) GTPase-activating protein, Gcs1.
Biochem. J.
Venkateswarlu, K., Gunn-Moore, F., Tavare, J. M. and Cullen, P. J. (
). EGF- and NGF-stimulated translocation of cytohesin-1 to the plasma membrane of PC12 cells requires PI 3-kinase activation and a functional cytohesin-1 PH domain.
J. Cell Sci.
Venkateswarlu, K., Brandom, K. G. and Lawrence, J. L. (
). Centaurin-alpha1 is an in vivo phosphatidylinositol 3,4,5-trisphosphate-dependent GTPase-activating protein for ARF6 that is involved in actin cytoskeleton organization.
J. Biol. Chem.
Venkateswarlu, K., Hanada, T. and Chishti, A. H. (
). Centaurin-{alpha}1 interacts directly with kinesin motor protein KIF13B.
J. Cell Sci.
Whitley, P., Gibbard, A. M., Koumanov, F., Oldfield, S., Kilgour, E. E., Prestwich, G. D. and Holman, G. D. (
). Identification of centaurin-alpha2: a phosphatidylinositide-binding protein present in fat, heart and skeletal muscle.
Eur. J. Cell Biol.
Zemlickova, E., Dubois, T., Kerai, P., Clokie, S., Cronshaw, A. D., Wakefield, R. I., Johannes, F. J. and Aitken, A. (
). Centaurin-alpha(1) associates with and is phosphorylated by isoforms of protein kinase C.
Biochem. Biophys. Res. Commun.